Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real world renal safety study after switching from Long-Term Nucleotide Analogue Treatment to Tenofovir Alafenamide in ChronicHepatitis B patients

Trial Profile

Real world renal safety study after switching from Long-Term Nucleotide Analogue Treatment to Tenofovir Alafenamide in ChronicHepatitis B patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2018

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Adefovir dipivoxil; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2018 New trial record
    • 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top